PumasAI Now Offering its Modeling and Simulation Software Free to Academic Research Institutions

Pumas-AI Inc, a science-first organization that turns data into life-saving decisions faster, announced today that it is now opening its powerful modeling and simulation software to all global academic institutions and researchers free of charge.

This pro-bono program provides the use of the Pumas^® tool, a high-performance analytical software suite that allows users to perform all pharmaceutical modeling and simulation with the power of artificial intelligence and machine learning on one integrated platform. The tool features the ability to perform the following analyses in the same system:

• Nonlinear Mixed Effect (NLME)
• Optimal Design
• Bayesian
• Stochastic Approximation of Expectation-Maximization (SAEM)
• Clinical Trial Simulations
• Machine Learning (ML)
• Noncompartmental PK Analysis (NCA)
• Bioequivalence (BE)

“We want to give back and allow students, post-docs, and researchers worldwide to focus acutely on the research; we’ll provide the tools,” said Dr. Vijay Ivaturi, Co-Founder and CEO at PumasAI. “This is funded by taking a portion of the revenue at PumasAI to contribute back to society in the best way that we know how – by furthering knowledge in clinical pharmacology, pharmacometrics, and drug development.”

To be eligible for complimentary access, applicants must:

• Be an accredited educational institution
• Specify that the work is for educational, non-commercial use
• Submit a completed registration form by clicking here

Ivaturi added, “Academic institutions instilled the skills in us to build Pumas products. And the best way to pay them back and empower the future of pharmaceutical research is to make these next-level tools available for free.”

To learn more about Pumas for Academia, visit https://pumas.ai/for-academia

About PumasAI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare for patients. Proprietary software developed by the company includes the Pumas^® suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, and Lyv, a clinical decision support system that leverages patient history and targeted medical data for personalized healthcare delivery. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more. For additional information, visit www.pumasai.com.

###